 | • レポートコード：MRC2305A058 • 出版社/出版日：Transparency Market Research / 2023年3月14日 • レポート形態：英文、PDF、232ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥840,275 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,275,275 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,710,275 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の当調査レポートによると、世界の医療用食品市場規模が、2023年の230億ドルから2031年に440億ドルとなり、予測期間中に年平均7.5%で成長すると推測されています。本レポートは、医療用食品の世界市場について徹底的に分析・調査を行い、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要インサイト、製品別（丸薬、粉末、液体、その他）分析、疾患別（希少疾病、がん、神経・精神疾患、代謝性疾患、その他）分析、投与経路別（経口、経腸）分析、流通チャネル別（薬局・ドラックストア、オンライン、スーパーマーケット＆ハイパーマーケット、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況など、以下の項目を整理しています。また、Nutricia (Danone)、Nestlé S.A.、Abbott Laboratories、Mead Johnson Nutrition、Fresenius Kabi、Friso、Morinaga Milk Industry、Primus Pharmaceuticals, Inc.、Targeted Medical Pharma, Inc.、Medtrition, Inc.など、主要企業情報を含んでいます。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・主要インサイト ・世界の医療用食品市場規模：製品別 - 丸薬型医療用食品の市場規模 - 粉末型医療用食品の市場規模 - 液体型医療用食品の市場規模 - その他製品の市場規模 ・世界の医療用食品市場規模：疾患別 - 希少疾病における市場規模 - がんにおける市場規模 - 神経・精神疾患における市場規模 - 代謝性疾患における市場規模 - その他疾患における市場規模 ・世界の医療用食品市場規模：投与経路別 - 経口投与における市場規模 - 経腸投与における市場規模 ・世界の医療用食品市場規模：流通チャネル別 - 薬局・ドラックストアチャネルの市場規模 - オンラインチャネルの市場規模 - スーパーマーケット＆ハイパーマーケットチャネルの市場規模 - その他チャネルの市場規模 ・世界の医療用食品市場規模：地域別 - 北米の医療用食品市場規模 - ヨーロッパの医療用食品市場規模 - アジア太平洋の医療用食品市場規模 - 中南米の医療用食品市場規模 - 中東・アフリカの医療用食品市場規模 ・競争状況 |
Medical Foods Market – Scope of Report
TMR’s report on the global medical foods market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global medical foods market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global medical foods market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the medical foods market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global medical foods market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global medical foods market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global medical foods market.
The report delves into the competitive landscape of the global medical foods market. Key players operating in the global medical foods market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global medical foods market profiled in this report.
Key Questions Answered in Global Medical Foods Market Report
• What is the sales/revenue generated by medical foods across all regions during the forecast period?
• What are the opportunities in the global medical foods market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?
Medical Foods Market – Research Objectives and Research Approach
The comprehensive report on the global medical foods market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global medical foods market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global medical foods market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Medical Foods Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
5. Key Insights
5.1. Important market developments
5.2. Top 3 Players Operating in the Market Space
5.3. New competitive market entrants
5.4. Medical food regulation overview
5.5. Reimbursement Scenario
5.6. Overview of the Distribution Channel of Medical Foods in various diseases along with examples
6. Global Medical Foods Market Analysis and Forecast, by Product Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product Type, 2017–2031
6.3.1. Pills
6.3.2. Powder
6.3.3. Liquid
6.3.4. Others
6.4. Market Attractiveness Analysis, by Product Type
7. Global Medical Foods Market Analysis and Forecast, by Disease Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Disease Type, 2017–2031
7.3.1. Orphan Disease
7.3.1.1. Duchenne Muscular Dystrophy (DMD)
7.3.1.2. Sickle Cell Anemia
7.3.1.3. Hemophilia
7.3.1.4. Others
7.3.2. Cancer
7.3.3. Neurological & Psychological Disorders
7.3.4. Metabolic Disorders
7.3.5. Pain Management
7.3.6. Gastrointestinal Disorders
7.3.7. Ophthalmology
7.3.8. Diabetes
7.3.9. Phenylketonuria (PKU)
7.3.10. Epilepsy
7.4. Market Attractiveness Analysis, by Disease Type
8. Global Medical Foods Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Route of Administration, 2017–2031
8.3.1. Oral
8.3.2. Enteral
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Medical Foods Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Distribution Channel, 2017–2031
9.3.1. Pharmacies & Drug Stores
9.3.2. Online Channels
9.3.3. Supermarkets & Hypermarkets
9.3.4. Others
9.4. Market Attractiveness Analysis, by Distribution Channel
10. Global Medical Foods Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Medical Foods Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product Type, 2017–2031
11.2.1. Pills
11.2.2. Powder
11.2.3. Liquid
11.2.4. Others
11.3. Market Value Forecast, by Disease Type, 2017–2031
11.3.1. Orphan Disease
11.3.1.1. Duchenne Muscular Dystrophy (DMD)
11.3.1.2. Sickle Cell Anemia
11.3.1.3. Hemophilia
11.3.1.4. Others
11.3.2. Cancer
11.3.3. Neurological & Psychological Disorders
11.3.4. Metabolic Disorders
11.3.5. Pain Management
11.3.6. Gastrointestinal Disorders
11.3.7. Ophthalmology
11.3.8. Diabetes
11.3.9. Phenylketonuria (PKU)
11.3.10. Epilepsy
11.4. Market Value Forecast, by Route of Administration, 2017–2031
11.4.1. Oral
11.4.2. Enteral
11.5. Market Value Forecast, by Distribution Channel, 2017–2031
11.5.1. Pharmacies & Drug Stores
11.5.2. Online Channels
11.5.3. Supermarkets & Hypermarkets
11.5.4. Others
11.6. Market Value Forecast, by Country, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Product
11.7.2. By Disease Type
11.7.3. By Route of Administration
11.7.4. By Distribution Channel
11.7.5. By Country
12. Europe Medical Foods Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product Type, 2017–2031
12.2.1. Pills
12.2.2. Powder
12.2.3. Liquid
12.2.4. Others
12.3. Market Value Forecast, by Disease Type, 2017–2031
12.3.1. Orphan Disease
12.3.1.1. Duchenne Muscular Dystrophy (DMD)
12.3.1.2. Sickle Cell Anemia
12.3.1.3. Hemophilia
12.3.1.4. Others
12.3.2. Cancer
12.3.3. Neurological & Psychological Disorders
12.3.4. Metabolic Disorders
12.3.5. Pain Management
12.3.6. Gastrointestinal Disorders
12.3.7. Ophthalmology
12.3.8. Diabetes
12.3.9. Phenylketonuria (PKU)
12.3.10. Epilepsy
12.4. Market Value Forecast, by Route of Administration, 2017–2031
12.4.1. Oral
12.4.2. Enteral
12.5. Market Value Forecast, by Distribution Channel, 2017–2031
12.5.1. Pharmacies & Drug Stores
12.5.2. Online Channels
12.5.3. Supermarkets & Hypermarkets
12.5.4. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. by Product Type
12.7.2. By Disease Type
12.7.3. By Route of Administration
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region
13. Asia Pacific Medical Foods Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product Type, 2017–2031
13.2.1. Pills
13.2.2. Powder
13.2.3. Liquid
13.2.4. Others
13.3. Market Value Forecast, by Disease Type, 2017–2031
13.3.1. Orphan Disease
13.3.1.1. Duchenne Muscular Dystrophy (DMD)
13.3.1.2. Sickle Cell Anemia
13.3.1.3. Hemophilia
13.3.1.4. Others
13.3.2. Cancer
13.3.3. Neurological & Psychological Disorders
13.3.4. Metabolic Disorders
13.3.5. Pain Management
13.3.6. Gastrointestinal Disorders
13.3.7. Ophthalmology
13.3.8. Diabetes
13.3.9. Phenylketonuria (PKU)
13.3.10. Epilepsy
13.4. Market Value Forecast, by Route of Administration, 2017–2031
13.4.1. Oral
13.4.2. Enteral
13.5. Market Value Forecast, by Distribution Channel, 2017–2031
13.5.1. Pharmacies & Drug Stores
13.5.2. Online Channels
13.5.3. Supermarkets & Hypermarkets
13.5.4. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. by Product Type
13.7.2. By Disease Type
13.7.3. By Route of Administration
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region
14. Latin America Medical Foods Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product Type, 2017–2031
14.2.1. Pills
14.2.2. Powder
14.2.3. Liquid
14.2.4. Others
14.3. Market Value Forecast, by Disease Type, 2017–2031
14.3.1. Orphan Disease
14.3.1.1. Duchenne Muscular Dystrophy (DMD)
14.3.1.2. Sickle Cell Anemia
14.3.1.3. Hemophilia
14.3.1.4. Others
14.3.2. Cancer
14.3.3. Neurological & Psychological Disorders
14.3.4. Metabolic Disorders
14.3.5. Pain Management
14.3.6. Gastrointestinal Disorders
14.3.7. Ophthalmology
14.3.8. Diabetes
14.3.9. Phenylketonuria (PKU)
14.3.10. Epilepsy
14.4. Market Value Forecast, by Route of Administration, 2017–2031
14.4.1. Oral
14.4.2. Enteral
14.5. Market Value Forecast, by Distribution Channel, 2017–2031
14.5.1. Pharmacies & Drug Stores
14.5.2. Online Channels
14.5.3. Supermarkets & Hypermarkets
14.5.4. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. by Product Type
14.7.2. By Disease Type
14.7.3. By Route of Administration
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-region
15. Middle East & Africa Medical Foods Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Product Type, 2017–2031
15.2.1. Pills
15.2.2. Powder
15.2.3. Liquid
15.2.4. Others
15.3. Market Value Forecast, by Disease Type, 2017–2031
15.3.1. Orphan Disease
15.3.1.1. Duchenne Muscular Dystrophy (DMD)
15.3.1.2. Sickle Cell Anemia
15.3.1.3. Hemophilia
15.3.1.4. Others
15.3.2. Cancer
15.3.3. Neurological & Psychological Disorders
15.3.4. Metabolic Disorders
15.3.5. Pain Management
15.3.6. Gastrointestinal Disorders
15.3.7. Ophthalmology
15.3.8. Diabetes
15.3.9. Phenylketonuria (PKU)
15.3.10. Epilepsy
15.4. Market Value Forecast, by Route of Administration, 2017–2031
15.4.1. Oral
15.4.2. Enteral
15.5. Market Value Forecast, by Distribution Channel, 2017–2031
15.5.1. Pharmacies & Drug Stores
15.5.2. Online Channels
15.5.3. Supermarkets & Hypermarkets
15.5.4. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. by Product Type
15.7.2. By Disease Type
15.7.3. By Route of Administration
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (by tier and size of companies)
16.2. Competitive Business Strategies
16.3. Company Profiles
16.3.1. Nutricia (Danone)
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Nestlé S.A.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Abbott Laboratories
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Mead Johnson Nutrition
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Fresenius Kabi
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Friso
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Morinaga Milk Industry
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Primus Pharmaceuticals, Inc.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Targeted Medical Pharma, Inc.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Medtrition, Inc.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview